Israel

Check-Cap Ltd. Announces $4.0 Million Registered Direct Offering

Retrieved on: 
Monday, April 20, 2020
Placement, Stock market, United States securities law

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

Key Points: 
  • H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
  • The gross proceeds to Check-Cap from this offering are expected to be approximately $4.0 million, before deducting the placement agent's fees and other offering expenses.
  • Forward looking statements in the press release include, but not limited to, statements regarding the completion of the registered direct offering, the satisfaction of customary closing conditions related to the registered direct offering and the intended use of net proceeds from the registered direct offering.
  • Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov .

NanoPass Is Joining Forces With Pharma Partners in the Fight Against the COVID-19 Pandemic

Retrieved on: 
Monday, April 20, 2020
Vaccination, Vaccine, Virology, Microneedle, Antiviral drug, Medical specialties, Vaccines, Medicine, Biology

Since there is currently no proven antiviral therapy and herd immunity is likely months away, the race for finding a vaccine is in full swing on a global level.

Key Points: 
  • Since there is currently no proven antiviral therapy and herd immunity is likely months away, the race for finding a vaccine is in full swing on a global level.
  • Considering this urgent need, NanoPass is joining forces with leading vaccine and immunotherapy companies around the world and is sharing its proprietary MicronJet microneedle device to enable development of a safe, effective and affordable vaccine.
  • "The human skin is our first layer of defense against many infectious diseases," says Yotam Levin, MD, CEO of NanoPass.
  • It is supported by extensive clinical data and regulatory approvals in most major markets including the US, Europe, China and Korea.

NanoPass Is Joining Forces With Pharma Partners in the Fight Against the COVID-19 Pandemic

Retrieved on: 
Monday, April 20, 2020
Vaccination, Vaccine, Virology, Coronavirus, Branches of biology, Organisms, Biology

NES ZIONA, Israel, April 20, 2020 /PRNewswire/ -- Novel Coronavirus presents a global pandemic with unprecedented medical, economic and social scales.

Key Points: 
  • NES ZIONA, Israel, April 20, 2020 /PRNewswire/ -- Novel Coronavirus presents a global pandemic with unprecedented medical, economic and social scales.
  • Considering this urgent need, NanoPass is joining forces with leading vaccine and immunotherapy companies around the world and is sharing its proprietary MicronJet microneedle device to enable development of a safe, effective and affordable vaccine.
  • "The human skin is our first layer of defense against many infectious diseases," says Yotam Levin, MD, CEO of NanoPass.
  • It is supported by extensive clinical data and regulatory approvals in most major markets including the US, Europe, China and Korea.

IceCure Continues Global Expansion to Freeze Tumors

Retrieved on: 
Monday, April 20, 2020
Medicine, Medical specialties, Clinical medicine, Interventional radiology, Medical terminology, Terumo, Interventional oncology, Cryoablation, Minimally invasive procedure

CAESAREA, Israel, April 20, 2020 /PRNewswire/ --IceCure Medical (TASE: ICCM), a developer and marketer of minimally invasive cryoablation therapies for women's health and Interventional oncology markets, announced today the expansion of its distribution territory into Singapore with leading global medical company, Terumo Corporation (Tokyo: 4543, TRUMY:OTC US).

Key Points: 
  • CAESAREA, Israel, April 20, 2020 /PRNewswire/ --IceCure Medical (TASE: ICCM), a developer and marketer of minimally invasive cryoablation therapies for women's health and Interventional oncology markets, announced today the expansion of its distribution territory into Singapore with leading global medical company, Terumo Corporation (Tokyo: 4543, TRUMY:OTC US).
  • "We are proud to see the execution of our milestone agreement with Terumo progressing well with our first order in Singapore, where we have regulatory approval," said Eyal Shamir, CEO of IceCure.
  • Its technology is a safe, effective, non-invasive alternative to surgical tumor removal that is easily performed in a short procedure.
  • The company has a wholly-owned subsidiary in the United States, IceCure Medical Inc., with offices in New Jersey.

Saguna Networks Announces New CEO

Retrieved on: 
Monday, April 20, 2020
Cloud infrastructure, VocalTec, Cloud computing, ECI Telecom, Telecommunications, Companies, Information and communications technology

YOKNEAM, Israel, April 20, 2020 /PRNewswire/ -- Saguna , the developer of advanced multi-access edge cloud (MEC) computing solution that transforms communication networks into powerful edge cloud computing platforms, announced today that Ido Gur has been appointed as the company's CEO.

Key Points: 
  • YOKNEAM, Israel, April 20, 2020 /PRNewswire/ -- Saguna , the developer of advanced multi-access edge cloud (MEC) computing solution that transforms communication networks into powerful edge cloud computing platforms, announced today that Ido Gur has been appointed as the company's CEO.
  • He has previously served as CEO of GASNGO, CEO and President of VocalTec, and EVP Global Sales & Marketing of ECI Telecom.
  • "Ido's experience and capabilities are best suited to take Saguna to the next level," said Lior Fite, Saguna founder and the outgoing CEO.
  • Saguna, the Multi-Access Edge Cloud Computing pioneer, helps communication companies monetize, optimize & accelerate their networks.

Wavelength Pharmaceuticals Expands Supplies of Key Drug Ingredients for Critically Ill COVID-19 Patients

Retrieved on: 
Monday, April 20, 2020
Managed care, Infectious diseases, Pharmaceutical, Health, RTT, Health, Pharmaceutical industry in China, Pharmaceuticals policy, Pharmacy in China, Science and technology in the People's Republic of China, Midazolam, Pharmaceutical industry in Bangladesh, Drugs

Wavelength Pharmaceuticals, a leading supplier of active pharmaceutical ingredients (APIs), today reported that it has greatly expanded production of APIs for certain pharmaceutical products needed to manage respiratory critical care patients.

Key Points: 
  • Wavelength Pharmaceuticals, a leading supplier of active pharmaceutical ingredients (APIs), today reported that it has greatly expanded production of APIs for certain pharmaceutical products needed to manage respiratory critical care patients.
  • Demand for these products, including Midazolam, Cisatracurium, and Rocuronium, has skyrocketed as a result of the global coronavirus pandemic.
  • Our robust supply chain and impeccable regulatory track record are enabling us to quickly respond to the urgent need for life-saving care for critically ill COVID-19 patients.
  • We are honored to be able to offer these products and services to support customers and patients during these challenging times.

Compugen Announces Publication of BAY 1905254 Preclinical Data in Cancer Immunology Research

Retrieved on: 
Monday, April 20, 2020
Compugen, Medicine, Clinical medicine, Virotherapy, Cancer treatments, Cancer immunotherapy, Immunotherapy, Health

The preclinical studies, published in Cancer Immunology Research, a journal of the American Association for Cancer Research, were conducted in collaboration between Compugen and Bayer AG, with data demonstrating BAY 1905254 in vitro T cell activation and in vivo anti-tumor activity.

Key Points: 
  • The preclinical studies, published in Cancer Immunology Research, a journal of the American Association for Cancer Research, were conducted in collaboration between Compugen and Bayer AG, with data demonstrating BAY 1905254 in vitro T cell activation and in vivo anti-tumor activity.
  • ILDR2 is a novel therapeutic target in immuno-oncologydiscovered computationally by Compugen and licensed to Bayer under a research and development collaboration and license agreement.
  • BAY 1905254 is currently being evaluated by Bayer in a Phase 1 study as monotherapy and in combination with Keytruda in patients with advanced solid tumors.
  • "ILDR2's differentiated mode of action suggests that BAY 1905254 has the potential to expand treatment options for cancer patients unresponsive or refractory to existing immunotherapies."

RADCOM to Report First Quarter 2020 Results on Tuesday, May 12, 2020

Retrieved on: 
Monday, April 20, 2020
Telecommunications, Radcom Ltd, Technology, Internet of things, Mobile telecommunications, Network performance, RDCM, 5G, Service assurance, RadCom

TEL AVIV, Israel, April 20, 2020 /PRNewswire/ -- RADCOM Ltd. (NASDAQ: RDCM), today announced that it will report its financial results for the first quarter ending March 31, 2020, on Tuesday, May 12, 2020, before the opening of trade on the Nasdaq Stock Market.

Key Points: 
  • TEL AVIV, Israel, April 20, 2020 /PRNewswire/ -- RADCOM Ltd. (NASDAQ: RDCM), today announced that it will report its financial results for the first quarter ending March 31, 2020, on Tuesday, May 12, 2020, before the opening of trade on the Nasdaq Stock Market.
  • RADCOM (Nasdaq: RDCM) is the leading expert in 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G.
  • RADCOM Network Intelligence consists of RADCOM Network Visibility, RADCOM Service Assurance, and RADCOM Network Insights.
  • The RADCOM Network Intelligence suite offers intelligent, container-based, on-demand, solutions to deliver network analysis from the RAN to the Core for 5G assurance.

Nova to Report First Quarter Financial Results on May 14, 2020, Expects to Meet High End of Guidance

Retrieved on: 
Monday, April 20, 2020
Nova Measuring Instruments, Nova, Companies

Nova delivers continuous innovation by providing state-of-the-art high-performance metrology solutions for effective process control throughout the semiconductor fabrication lifecycle.

Key Points: 
  • Nova delivers continuous innovation by providing state-of-the-art high-performance metrology solutions for effective process control throughout the semiconductor fabrication lifecycle.
  • Nova's product portfolio, which combines high- precision hardware and cutting-edge software, provides its customers with deep insight into the development and production of the most advanced semiconductor devices.
  • Nova's unique capability to deliver innovative X-ray and Optical solutions enable its customers to improve performance, enhance product yields and accelerate time to market.
  • Nova Measuring Instruments Ltd. does not assume any obligation to update the forward-looking information contained in this press release.

Equinom's Novel Cultivation Methods Transform Global Sesame Space, Boosting Security and Profitability

Retrieved on: 
Monday, April 20, 2020
Crops, Flora of Nepal, Sesame, Spices, Agronomy, Plants, Agriculture

The move kicks off a new era of heightened profitability and increased market stability for the ancient crop.

Key Points: 
  • The move kicks off a new era of heightened profitability and increased market stability for the ancient crop.
  • Results so far include the introduction of a fresh influx of land now dedicated to the cultivation of sesame totaling 100K acres worldwide to meet burgeoning demands.
  • Newly emerging growers in the US and Australia are eagerly adopting cultivation of sesame locally.
  • Equinom's breeding methods are proving to be instrumental in boosting access to high-value sesame.